EAU 2013 - Programme Book - YouMed

Sunday, 17 March
Sponsored Session
17.45 - 19.15 Nocturia: Definitive diagnosis for better patient outcomes
Yellow Hall 1-2-3 - Level N1
Symposium
Chair: P.E. Van Kerrebroeck, Maastricht (NL)
Welcome and introduction
P.E. Van Kerrebroeck, Maastricht (NL)
Breaking the patient stereotype
A.J. Wein, Philadelphia (US)
What is different about nocturia?
M. Oelke, Hanover (DE)
Non-antidiuretic vs antidiuretic pharmacotherapy for nocturia
J. Weiss, New York (US)
Round-up of patient case studies
P.E. Van Kerrebroeck, Maastricht (NL)
Questions and answers
Aims and objectives
This Ferring Pharmaceuticals-sponsored symposium aims to provide an overview of the variety of clinical
characteristics of patients with nocturia, and the multifactorial nature of the mechanism of the disease. The
symposium will:
• Provide an overview of the prevalence and consequences of nocturia (Philip Van Kerrebroeck, the
Netherlands)
• Discuss case studies of patients with nocturia and their diagnoses through audience interaction (Alan Wein,
USA)
• Review current understanding of the mechanism of nocturia and discuss treatment algorithms and
guidelines (Matthias Oelke, Germany)
• Summarise the evidence for efficacy of available pharmacotherapies for nocturia (Jeffrey Weiss, USA)
Sponsored by FERRING PHARMACEUTICALS
EAU Milan 2013
411
Sponsored Sessions